A randomized phase II trial comparing two paclitaxel (P)-cisplatin (C) containing chemoradiation (CRT) regimens as adjuvant therapy in resected gastric cancer (RTOG Intergroup #0114)

Schwartz, G. K.; Winter, Katarzyna; Minsky, Bruce D.; Janjan, Nora A.; Schaefer, P.; Thomson, John W.; Rani, Anju; Gross, Howard M.; Willett, Christopher G.; Kelsen, D.

doi:10.1200/jco.2005.23.16_suppl.4020

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, elderly patients tolerated the cisplatin-containing regimen poorly, and it is our impression that, for the schedule we tested, the mtd for patients over 70 years of age may be cohort 1 (12 weeks of infusional 5fu with radiotherapy). One strategy to optimize the balance of acute toxicities and survival outcomes in gastric cancer is an assessment of alternative chemoradiation regimens in the adjuvant setting [17][18][19][20][21][22][23] . The use of infusional 5fu may itself improve survival and toxicity outcomes.…”

Section: Discussionmentioning

confidence: 99%

Adjuvant Chemoradiation for Gastric Cancer with Infusional 5-Fluorouracil and Cisplatin: A Phase I Study

et al. 2010

View full text Add to dashboard Cite

ObjectiveThis phase i study aimed to determine the maximal tolerated dose of cisplatin administered every 2 weeks with infusional 5-fluorouracil (5fu) and concurrent radiation therapy (rt) in patients after complete resection of gastric adenocarcinoma. MethodsPatients with resected stage ib to iv (M0) gastric adenocarcinoma were treated with 12 weeks of infusional 5fu (200 mg/m 2 daily) and with rt (45 Gy in 25 fractions starting on day 16). Cisplatin was administered in escalating doses (0,20, 30, and 40 mg/m 2 ) in weeks 1, 3, 5, and 7. In the final cohort, patients received an additional dose of cisplatin (40 mg/m 2 ) in week 9. ResultsAmong the 34 patients [median age: 56 years (range: 31-77 years)] who were assessable for toxicity, 5 experienced dose-limiting toxicities: 1 sepsis (cohort 1), 1 fatigue (cohort 2), 3 upper gastrointestinal toxicity (1 in cohort 2, 2 in cohort 5). Cohort 5 exceeded the maximal tolerated dose. Median follow-up was 2.5 years (range: 0.3-5 years). The 3-year overall and relapse-free survival rates were 86% and 71% respectively; median survival was not reached. ConclusionsCisplatin was well tolerated in combination with infusional 5fu and rt, showing promising activity in the adjuvant treatment of gastric cancer. Infusional 5fu 200 mg/m 2 daily for 12 weeks with cisplatin 40 mg/m 2 in weeks 1, 3, 5, and 7 and with concurrent rt 45 Gy in 25 fractions, starting at day 16, is being explored in a phase ii study at our institution.

show abstract

Section: Discussionmentioning

confidence: 99%

Adjuvant Chemoradiation for Gastric Cancer with Infusional 5-Fluorouracil and Cisplatin: A Phase I Study

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Norint pagrįsti adjuvantinio chemospindulinio gydymo skyrimą ir siekiant nustatyti jo įtaką išgyvenamumui, atliekami tyrimai taikant konformalų spindulinį gydymą ir įtraukiant naujus chemoterapinius preparatus. Atliekami II fazės tyrimai taikant pooperacinį chemospindulinį gydymą su naujais preparatais ir jų skyrimo būdais: cisplatina, epirubicinu, ilgalaike 5-FU infuzija, paklitakseliu, Kapecitabinu rodo pakankamai gerą toleranciją ir panašų toksiškumą kaip ir INT 0116 studijoje (25)(26)(27).…”

Section: Rezultataiunclassified

Adjuvant therapy after curative resection with D2 lymphadenectomy for gastric cancer: Results of a prospective clinical trial

Markelis¹,

Endzinas²,

Kiudelis³

et al. 2009

Medicina

View full text Add to dashboard Cite

Objective. Adjuvant chemoradiation for gastric cancer is used more frequently, but there is no general opinion about the effect of this treatment. The aim of this study was to compare adjuvant chemoradiation with adjuvant chemotherapy after radical operation for stomach cancer. Material and methods. A total of 133 patients were included in this prospective study. Sixty-three patients after curative gastrectomy and D2 lymphadenectomy for gastric cancer were assigned to the chemoradiotherapy group and 70 to the chemotherapy group. The groups were identical by age, sex, and cancer stages. Toxicity was evaluated by the WHO scale, and survival was evaluated by the Kaplan-Meier method. Results. Grade III and IV toxicity was found more frequently in the chemoradiation group than in the chemotherapy group (44.4% and 7.1%, respectively; P<0.0001). Treatment was not finished in 27% of patients in the chemoradiation group and 11.4% in the chemotherapy group (P=0.03). Overall survival was better in the chemotherapy group as compared with the chemoradiation group (P=0.039). Median survival for patients with stage III and IV cancer was 41 months in the chemotherapy group and 18 months in the chemoradiation group (P=0.085). Survival of patients with stage IIIA cancer in the chemotherapy group was significantly better (P=0.005). Conclusions. Median survival is shorter in the adjuvant chemoradiation group after curative gastrectomy for gastric cancer as compared with the adjuvant chemotherapy group. Adjuvant chemoradiation is more toxic and should be recommended only for patients with advanced-stage cancer.

show abstract

Conformal radiotherapy in the adjuvant treatment of gastric cancer: Review of 82 cases

Kassam

Lockwood

O’Brien

et al. 2006

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

A randomized phase II trial comparing two paclitaxel (P)-cisplatin (C) containing chemoradiation (CRT) regimens as adjuvant therapy in resected gastric cancer (RTOG Intergroup #0114)

Cited by 5 publications

References 0 publications

Adjuvant Chemoradiation for Gastric Cancer with Infusional 5-Fluorouracil and Cisplatin: A Phase I Study

Adjuvant Chemoradiation for Gastric Cancer with Infusional 5-Fluorouracil and Cisplatin: A Phase I Study

Adjuvant therapy after curative resection with D2 lymphadenectomy for gastric cancer: Results of a prospective clinical trial

Conformal radiotherapy in the adjuvant treatment of gastric cancer: Review of 82 cases

Contact Info

Product

Resources

About